Sandip Patel, MD, compares the previous approach to genomic profiling in non–small cell lung cancer as being like finding a street on a map, whereas recent advancements in specificity for various mutations with next-generation sequencing are like finding the correct address. He also recounts an experience with a young patient with NSCLC, despite having no smoking history, to illustrate the importance of testing appropriately. After sending the patient for a DNA plus RNA-based tissue panel, Dr Patel identified a ROS1 mutation and started the patient on entrectinib, which has since resolved his central nervous system metastases.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Molecular Testing in mNSCLC: Digging a Little Deeper Makes All the Difference - Medscape - Nov 22, 2021.